Clinical trial
Soluble CD23 Expression in Asthma Patients Treated With OMA
NCT00226200 · University of Mississippi Medical Center, Other · Terminated
Key facts
| NCT number | NCT00226200 |
|---|---|
| Title | Soluble CD23 Expression in Asthma Patients Treated With OMA |
| Official title | Soluble CD23 Expression as a Marker of Immunomodulation and CLinical Response in Asthma Patients Treated With Omalizumab |
| Lead sponsor | University of Mississippi Medical Center, Other |
| Collaborators | Novartis Pharmaceuticals Industry |
| Status | Terminated |
| Study type | Interventional |
| Conditions | Asthma |
| Intervention type | Drug |
| Interventions | Omalizumab |
| Enrollment | 80 |
| Start date | Nov 1, 2004 |
| Primary completion | Oct 1, 2007 |
| Completion | Oct 1, 2007 |
| First posted | Sep 26, 2005 |
| Last update posted | Dec 1, 2008 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: